HEALTHJun 13 · 13:22 UTCSTAT NEWSLizzy Lawrence

STAT+: FDA approves Sanofi diabetes drug for children with stage 3 diabetes

The FDA approved Sanofi's teplizumab for children aged 8 and older with stage 3 diabetes. The drug underwent a speedy review program but the agency missed its decision deadline of April 21. Sanofi requested to withdraw the drug from the program after Tracy Beth Høeg, a former top drug regulator, disagreed with a staff approval decision.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

FDAorganizationSanofiorganizationteplizumabtopicMarty MakarypersonTracy Beth Høegpersontype 1 diabetestopicstage 3 diabetestopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHMay 6 · 16:16 UTC
STAT+: Sanofi asks to pull diabetes drug out of FDA voucher program after political appointee interfered with review
HEALTHMay 7 · 13:47 UTC
STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more
HEALTHJun 5 · 13:17 UTC
STAT+: Pharmalittle: We’re reading about Roche accusing U.S. of ‘blackmail,’ a ruling on skinny labels, and more
HEALTHMay 18 · 17:05 UTC
STAT+: AstraZeneca picks up FDA approval for hypertension drug
HEALTHMay 27 · 13:33 UTC
STAT+: Pharmalittle: We’re reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more
HEALTHMay 15 · 09:00 UTC
FDA Blocked Melanoma Drug as Confusion Reigned Under Makary